Pharma, Biotech and Medtech 2018 in Review

04 March 2019

Evaluate

Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong

The Vantage 2018 in Review paints a mixed picture for biopharma and medtech in 2018. Key indicators on share price and dealmaking showed weakness, but there are signs of health from the industry in IPO outcomes, venture financing activity, and FDA drug approvals.

Report Highlights

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more